Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.London-based Amarin Corp, a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease, plans to retain a financial adviser to review its alternatives after potential buyers and partners showed interest in acquiring it.
Subscribe to our email newsletter
Amarin has two final-stage human tests of its advanced experimental cholesterol drug AMR101.
Bloomberg.com has quoted San Francisco-based Wedbush Securities analyst Duane Nash as saying that the cholesterol drug may lure buyers as it has minimal risk of rejection by regulators and there is a growing need for large pharmaceutical companies to augment their cardiovascular drug portfolios.
Also, AMR101 is a direct competitor for GlaxoSmithKline’s Lovaza, the only similar prescription drug approved in the US.
Reportedly, drug makers such as Pfizer, AstraZeneca and Merck & Co, who already make cholesterol pills, may be interested in buying Amarin.
Amarin CEO Joe Zakrzewski said their cholesterol drug may be safer than Lovaza.